Enanta Pharmaceuticals (ENTA) - Stock & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US29251M1062

Enanta Pharmaceuticals, Inc. is a biotechnology company that focuses on discovering and developing small molecule drugs to combat viral infections and liver diseases. They have a diverse product pipeline that includes EDP-514, currently in phase 1b clinical development for the treatment of chronic hepatitis B virus (HBV) infections.

In addition to EDP-514, Enanta Pharmaceuticals also has EDP-938 and EDP-323 in phase II clinical development to address respiratory syncytial virus, as well as EDP-235 for human coronaviruses. They are also known for Glecaprevir, a drug already on the market for treating chronic hepatitis C virus (HCV) infections.

The company's strategic partnerships are crucial to their success. Enanta Pharmaceuticals collaborates with Abbott Laboratories to develop, manufacture, and market HCV NS3 and NS3/4A protease inhibitor compounds such as paritaprevir and glecaprevir.

Established in 1995 and located in Watertown, Massachusetts, Enanta Pharmaceuticals continues to strive towards innovative solutions for pressing healthcare challenges. For more information, visit their official website: https://www.enanta.com.

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Enanta Pharmaceuticals (ENTA) - Stock & Dividends

ENTA Stock Overview

Market Cap in USD 294m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 2013-03-21

ENTA Stock Ratings

Growth 5y -5.15
Fundamental -85.5
Dividend -
Rel. Performance vs Sector -8.81
Analysts 3.63/5
Fair Price Momentum 12.13 USD
Fair Price DCF -

ENTA Dividends

Yield 12m 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Payout Consistency 0.0%

ENTA Growth Ratios

Growth 12m -51.87%
Growth Correlation 12m -28%
Growth Correlation 3m 14%
CAGR 5y -31.39%
Sharpe Ratio 12m -0.93
Alpha vs SP500 12m -75.08
Beta vs SP500 5y weekly 0.82
ValueRay RSI 47.33
Volatility GJR Garch 1y 60.42%
Price / SMA 50 -13.9%
Price / SMA 200 0.95%
Current Volume 160.5k
Average Volume 20d 143.6k

External Links for ENTA Stock

News
Wall Street JournalBenzingaYahoo Finance
Tweets
X (Twitter)Stocktwits
Fund Manager Positions
DataromaStockcircle
What is the price of ENTA stocks?
As of May 09, 2024, the stock is trading at USD 12.76 with a total of 160,469 shares traded.
Over the past week, the price has changed by -5.90%, over one month by -22.00%, over three months by +3.24% and over the past year by -62.83%.
What is the forecast for ENTA stock price target?
According to ValueRays Forecast Model, ENTA Enanta Pharmaceuticals will be worth about 13.5 in May 2025. The stock is currently trading at 12.76. This means that the stock has a potential upside of +5.64%.
Issuer Forecast Upside
Wallstreet Target Price 22.3 74.7
Analysts Target Price 27.9 119
ValueRay Target Price 13.5 5.64